Background: Clinical activity is difficult to assess by traditional response endpoints in patients with advanced prostate cancer. We used clinical benefit response to assess the activity of vinorelbine (Navelbine®) in patients with hormone-refractory prostate cancer.
Introduction
New treatment alternatives are needed for hormonerefractory prostate cancer because available chemotherapy produces disappointing results when traditional endpoints are used. Furthermore, response is difficult to assess because patients often lack measurable disease. Metastases typically occur in the bone, which is difficult to evaluate by bone scan because bone repair processes and disease flares resemble progressive disease. Prostate specific antigen (PSA) has been used for screening, but its role as a clinical endpoint is controversial [1] . Some patients benefit from chemotherapy as manifested by decreased pain or improved functional status. In view of the goal of treating hormone-refractory prostate cancer, palliation, it is appropriate to consider alternative endpoints that might substantiate the clinical benefit of chemotherapy.
Vinorelbine (Navelbine®) is a theoretically attractive alternative for advanced prostate cancer because it is active in other malignancies and has a modest toxicity profile. We conducted a phase II trial to assess the clinical benefit of vinorelbine in patients with hormonerefractory prostate cancer. The primary endpoint was derived from a palliative endpoint for advanced pancreas cancer [2] , another malignancy associated with tumorrelated symptoms and in which chemotherapy has produced disappointing results as measured by traditional endpoints. Clinical benefit was measured by two common debilitating signs or symptoms in patients with advanced prostate cancer, pain and functional impairment, as well as by tumor response, if measurable. The preliminary results of this study were reported previously [3] .
Patients and methods

Patient selection
Eligble patients had metastatic prostate cancer refractory to hormonal therapy (defined as progressive disease following bilateral orchiectomy or hormonal therapy), no prior chemotherapy, Karnofsky performance status >50, serum PSA > 10 ng/ml, granulocytes 2=2000/mm 3 , platelets 5; 100,000/mm 3 , hemoglobin ^9 g/dl, creatinine ^2.5 mg/dl, total bilirubin <2.0 mg/dl, SGOT < 3 times the upper limit of normal, no brain metastases, no peripheral neuropathy, and stable pain during screening. Patients were excluded if, at baseline, they had Karnofsky performance >80, analgesic consumption $10 morphine-equivalent mg/day, and visual analogue scale score of < 2 cm. All patients gave written informed consent in accordance with federal, state, and institutional guidelines.
Treatment
Vinorelbine was administered weekly for the first eight weeks and then every two weeks. The initial dose was 30 mg/m 2 . After the first six patients experienced granulocytopenia requiring dose delays, the dose was reduced to 22 mg/m 2 . Antiemetics and growth factors were not used prophylactically and were initiated at the investigators' discretion. Radiation therapy and steroids were not initiated during the study; LHRH analogues could be continued if initiated before the study. Dose modifications were based on hematologic parameters obtained on the day of treatment and on the presence of fever or sepsis after the previous cycle. The dose was reduced by 50% if the granulocyte count was 1500-1999/mm 3 or platelet count was 75,000-99,999/mm 3 . The dose was delayed one week if the granulocyte count was < 1500/mm 3 or platelet count was < 75,000/mm 3 . The patient was removed from study if dose was delayed for more than three weeks. Finally, the dose was reduced by 25% if the granulocyte count waŝ 2,000/mm 3 and platelet count was ^ 100,000/mm 3 and 1) fever or sepsis was present after the previous cycle or 2) the dose was delayed for more than 2, but less than 3, weeks.
Assessments and evaluation
Each patient was screened for two weeks before the first treatment by performing history and physical examination, Karnofsky performance status, pain visual analogue score, analgesic consumption, hematologic parameters, serum chemistry tests, prostate specific antigen (PSA) test, chest X-ray, urinalysis, bone scan, and X-rays of symptomatic bone lesions. During treatment, Karnofsky performance status and pain visual analogue scale were determined weekly for the first eight weeks, then every two weeks. Pain intensity was assessed on a 10 cm visual analogue scale on which 0 cm = no pain and 10 cm = intolerable pain [4] . At each clinic visit, the study nurse recorded the patient's mean analgesic consumption; converted it to morphine-equivalent units; and questioned the patient about symptoms and adverse experiences. Serum PSA levels were measured every four weeks. Bone scans were repeated every 12 weeks; other radiologic tests were repeated every 8-12 weeks as needed to evaluate measurable disease.
The primary efficacy endpoint was clinical benefit response. Evaluable patients had to remain on study ^8 weeks and receive at least four doses of vinorelbine. Clinical benefit response was defined by a positive response in one category for >12 weeks and at least stable assessment in the other two categories. A positive response in pain index was defined by a positive response in pain intensity or mean daily analgesic consumption, and stable assessment in the other pain parameter. A positive response in pain intensity was defined by a > 2 5 % improvement (i.e., decrease) from the baseline visual analogue scale measurement; a negative response was defined by > 25% worsening (i.e., increase). A positive response in mean daily analgesic consumption was defined by > 50% improvement (i.e., decrease) in mean daily analgesic consumption; a negative response was defined by > 2 5 % worsening (i.e., increase). A positive response in Karnofsky performance status was defined by improvement of one 10-point category from baseline. If the disease was measurable, it had to remain stable for the patient to be categorized as a responder.
Standard SWOG methods were used to determine sample size. If any responses were detected in the first 20 patients, 25 additional patients were enrolled to yield an 80% power of detecting a true response rate of 5= 20%.
Kaplan-Meier methods were used to estimate survival.
Results
Forty-nine men with hormone-refractory prostate cancer were enrolled (Table 1) . Twelve patients did not complete the eight-week treatment period because of rapid disease progression (n = 6), refusal to continue treatment (n = 3), and new underlying complications (n = 3). A total of 178 four-week courses of therapy (median 2. range 1-25) were administered. The median number of failed hormonal manipula- tions was 2 (range 1-6). Four patients received suramin (n = 2) or estramustine (n -2), but they were not excluded from analysis because of these protocol violations.
Clinical benefit, prostate specific antigen, and survival
Of 37 evaluable patients (Table 2 ), 14 (39%) were considered responders and had a median response duration of 6 months (range 3-24 months). Responses were manifested by improved pain index and Karnofsky performance status (n = 12), and pain index only (/; = 2). Eleven responders discontinued their analgesics for a median duration of 4 months (range 0.2-13.5 months). The median time to response was 3 weeks (range 1-16 weeks) in 23 patients, including 9 who were categorized as nonresponders because the duration of clinical benefit was < 12 weeks. The objective response rate could not be determined because only five patients had measurable disease at screening. Measurable lesion(s) remained stable in three patients and were not re-assessed in the remaining two.
PSA determinations were available in 30 of 37 evaluable patients. Of 14 clinical benefit responders, 9 (64%) experienced decreases in serum PSA levels, ranging from 10%-93% (median 32%); 4 patients had decreases of > 50%. Of 23 nonresponders, 12 (52%) had increases, 4 (17%) had decreases, 1 (4%) had an initial decrease followed by an increase.
The median duration of survival was 46 weeks (95% confidence interval: 28-54) for all 49 patients, including 17 patients (35%) censored at the time of analysis. The 14 clinical benefit responders had not yet reached their median duration of survival (range 26-116 weeks); the estimated 50-week survival was 55%.
Adverse effects
No unanticipated drug-related toxicities were observed. The first six patients developed neutropenia requiring dose delays, so the vinorelbine dose was subsequently reduced to 22 mg/m 2 . At this dose, 34 patients (79%) required dose modifications; but only one developed febrile neutropenia requiring hospitalization. Nine patients developed anemia requiring a total of twenty-eight blood transfusions. One additional patient required two blood transfusions because of rectal bleeding, which was not considered to be drug related. One patient also developed grade 3 thrombocytopenia and was given two platelet transfusions; however, this patient had a platelet count of only 65,000/mm 3 at baseline and therefore should not have been enrolled.
Thirteen patients (27%) experienced mild to moderate nausea, which was controlled with standard antiemetic therapy. One patient (2%) experienced severe nausea requiring prophylactic intravenous ondansetron with subsequent doses. Two patients (4%) experienced grade 1 vomiting; one (2%) had grade 2 vomiting. Nine patients (18%) complained of constipation; two (4%) reported diarrhea. Five patients (10%) experienced mild paresthesias manifested as numbness or tingling, which did not result in dose reductions or drug discontinuation. Five patients (10%) complained of tenderness and erythema at the site of drug administration; one patient (2%) experienced mild extravasation that resolved without sequelae. Four patients (8%) experienced mild fatigue. The remaining side effects were of mild or moderate intensity; reported in 2% of patients; and included chest pain, malaise, anorexia, dizziness, headache, tinnitus, blurred vision, insomnia, weight loss, mouth soreness, and mild alopecia.
Discussion
These phase II results provide evidence of the clinical benefit of vinorelbine in men with hormone-refractory prostate cancer based on improved pain index and performance status. The 39% clinical benefit response rate approximated that in two Canadian trials of patients with hormone-refractory prostate cancer. Mitoxantrone and low-dose prednisone produced palliative responses in 36% of 25 patients [5] and in 38% of 80 patients, 3 (8) which was significantly better than prednisone alone in the second trial [6] . As in our trial, the palliative endpoint was defined by improved pain index, but performance status was not included in their definition of palliative response [5, 6] . Another difference was that our minimal duration of palliative response (12 weeks) was twice that in the other trials [5, 6] . Nonetheless, our median duration of survival, 46 weeks, appears to be similar to that associated with mitoxantrone and lowdose prednisone [6] . Our phase II trial had several limitations. Nearly onefourth of patients were not assessable for clinical benefit response because they did not complete the eight-week treatment period. Half of these patients had rapid disease progression and another third developed underlying complications, which is consistent with the natural history of advanced prostate cancer. The 10-point change in Karnofsky performance status can be criticized as being clinically insignificant; however, this endpoint has relevance because the goal of treatment is palliation. Our criteria were adapted from a composite endpoint in which response required improvement in one category and stable assessment in the other two [2] ; none of our clinical benefit responses were manifested only by improved Karnofsky performance status. In the phase III trial of patients with pancreas cancer [2] , the treatment that produced a significant clinical benefit also produced a significant survival benefit, but no significant difference in response rate. Therefore, the treatment benefit might have been missed if only traditional response criteria had been used [2] .
The decreases in serum PSA levels were not always consistent with response to treatment in our study. Discordance has also been observed in other studies of patients with prostate cancer [7] [8] [9] [10] including the randomized evaluation of mitoxantrone and low-dose prednisone [6] .
Vinorelbine was well tolerated after the initial dose reduction and did not cause any unexpected toxicities, including those typically associated with chemotherapy, such as severe nausea, vomiting, and alopecia.
More studies are warranted to evaluate the benefit of vinorelbine alone and combined with other agents, as suggested by a phase I-II evaluation of vinorelbine and estramustine [11] . Our findings also add to the increasing evidence that palliative endpoints can be used to evaluate the role of chemotherapy in patients with nonmeasurable malignancies. Future studies should include quality-of-life assessments to ensure that clinical benefit is not offset by drug-related toxicity.
